William P. Quinn

William P. Quinn, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Bolt Biotherapeutics, Inc. and Viracta Therapeutics, Inc. The record holds 20 filings, for trades running from 10 December 2018 to 18 September 2026.

On the open market, the record shows 15 purchases worth €96k and 3 sales worth €51k. Netting one side against the other leaves €45k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants. 2026 to date brings 2 purchases and 3 sales.

A typical purchase (the median) is worth €2,020. On 6 out of 15 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

On 21 September 2026 came the latest disclosure, an open-market sale for €26k in Bolt Biotherapeutics, Inc. The last insider purchase was made public on 21 September 2026, 48 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 6 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.